Community pharmacists' role in preventing opioid substitution therapy-related deaths: a qualitative investigation into current UK practice (2019)

Background: Opioid substitution therapy involves prescribing of medical substitutes like methadone and buprenorphine to patients who are addicted to opioids. The majority of opioid substitution therapy dispensing in the UK is done by community pharmacists and they often see the patients on daily basis. It is unknown to what extent community pharmacists implement the policy to prevent overdose in patients receiving such treatment.
Objective: To explore what UK community pharmacists think about their role in preventing opium substitution-related deaths, their understanding of the risks associated with this substitution therapy and their views on what else community pharmacists could do to reduce such deaths. Setting Twenty four community pharmacists from two areas in UK (Worcestershire and Bath and North East Somerset).
Method: Between January and March 2013, community pharmacists providing opoin substitution therapy were interviewed in their pharmacy, using semi-structured interviews. Interpretative Phenomenology Analysis was used to analyse the data.
Main outcome measure: Thematically organised description of professional practice as reported by the participants against the clinical/practice guidance for opioid substitution therapy in UK.
Results: While participants felt their role to be essential in providing the service, they did not feel part of an integrated system. Participants' ability to act in risk situations was affected by their knowledge, confidence in intervening in such situation, as well as the support they receive in providing the service.
Conclusion: Participants reported large differences in how 'opioid substitution therapy' services are provided in community pharmacy. Lack of knowledge among some pharmacists and lack of support in providing the service resulted in some patients at high risk not having their risks acted upon.